CP
CPRX
Market ClosedCatalyst Pharmaceuticals, Inc.
US
182 employees
CEO: Richard John Daly
Founded: 2006
$31.49
+$0.00(+NaN%)
Market Cap
3.85B
Beta
0.74
52W Range
N/A
Dividend Yield
0.00%
CPRX Price Chart
Historical price performance
Loading MCI price data...
MarketCI Investment Signals
AI-synthesized investment signal for CPRX built from valuation, fundamentals, sentiment, and risk models
Investment Signal
BuyPass %
71.43%
Score
5/7
Fair Value Estimate
Cash flow analysis • Multiple methods
$142.24
AI Price Target
Machine learning • Price prediction
$33.19
Market Sentiment
News & social media analysis
0.00
Value Investor Price
Classic value analysis
$9.86
Financial Health
Bankruptcy risk assessment
19.86
Quality Score
Financial strength rating
4.00
AI Investment Grade
Deep analysis of filings & news
75.00
Key Investment Highlights
Important factors affecting CPRX investment thesis
Due Diligence Analysis
Investment criteria assessment and scoring
Overall Assessment
80.49% Excellent
Conditions Met
33.00/41.00
Due Diligence Score
80.49%Due Diligence Conditions
Investment analysis conditions and results
Pass | |
Pass | |
Fail | |
Pass | |
Pass | |
Pass |
Showing 1 to 6 of 46 conditions
Latest News
Recent news and updates for CPRX
No recent news available for CPRX
Core Financials
Loading financial data for CPRX...
Explore CPRX
CPRX in the Healthcare
Mid Cap